Clinical Trials on Non Small Cell Lung

Total 12680 results

Radiotherapy Oncology Centre "Santa Maria" Hospital
Paola Anselmo,MD; Michelina Casale,PhD; Fabio Trippa,MD

Recruiting

Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer (STARTNEWERA-OM)

NSCLC | Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Oligometastatic Disease | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Non-Small Cell Adenocarcinoma and other conditions

Italy
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

First-line Replacement Maintenance of Envafolimab in Advanced NSCLC (NSCLC)

Non-Small-Cell Lung

China
National Cancer Institute (NCI)

Completed

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL)

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Extensive Stage Small Cell Lung Carcinoma | Squamous Cell Lung Carcinoma | Recurrent Small Cell Lung Carcinoma

United States
University of Washington
National Cancer Institute (NCI)

Completed

FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging

Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7

United States
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Lung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

ROS1 Rearrangement Non-small Cell Lung Cancer | ALK Rearrangement Non-small Cell Lung Cancer

China
Shanghai Chest Hospital

Recruiting

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Non-small Cell Lung Cancer Metastatic | EGF-R Positive Non-Small Cell Lung Cancer

China
Washington University School of Medicine
Eli Lilly and Company

Completed

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer

United States
Royal Marsden NHS Foundation Trust
Bristol-Myers Squibb

Active, not recruiting

SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects (STILE)

Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage II

United Kingdom
Alliance Foundation Trials, LLC.
AstraZeneca

Active, not recruiting

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Regione Lombardia

Completed

Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial (ONC-MANILA12)

Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV

Italy
Maastricht Radiation Oncology
University Medical Center Groningen; The Netherlands Cancer Institute

Completed

Prophylactic Cranial Irradiation (PCI) vs Observation in Stage III NSCLC (NVALT11)

Non Small Cell Lung Cancer (NSCLC) | Stage III Non-Small Cell Lung Cancer | Radical Treatment

Netherlands
QLT Inc.

Terminated

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

Stage IV Non-small Cell Lung Cancer | Stage IIIb Non-small Cell Lung Cancer
QLT Inc.

Terminated

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

Stage IV Non-small Cell Lung Cancer | Stage IIIb Non-small Cell Lung Cancer
Washington University School of Medicine
Varian Medical Systems

Recruiting

Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Early Stage Non-small Cell Lung Cancer

United States
Mirati Therapeutics Inc.

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer

United States, Korea, Republic of, Italy, Spain, Czechia, Hungary, Netherlands, Canada, Australia, Austria, Belgium, Germany, Ireland, Israel, Poland, United Kingdom, Taiwan, Portugal
Worldwide Innovative Network Association
Pfizer; ARC Foundation for Cancer Research

Terminated

Survival Prolongation by Rationale Innovative Genomics (SPRING)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB

Israel, United States, Luxembourg, Spain
Indiana University

Completed

Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer

Healthy | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic

United States
Abramson Cancer Center of the University of Pennsylvania

Active, not recruiting

The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy

Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer

United States
National University Hospital, Singapore

Recruiting

Osimertinib for Advanced EGFR-positive NSCLC Patients

Non Small Cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Singapore
Greg Durm, MD
AstraZeneca; Indiana University School of Medicine

Terminated

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer

United States
National Cancer Institute, Naples

Active, not recruiting

MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer (MILES-3)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB

Italy
Zhejiang Provincial People's Hospital

Withdrawn

Abscopal Effect for Metastatic Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer | Radiotherapy | Metastatic Non-small Cell Lung Cancer | Thymalfasin
First People's Hospital of Hangzhou

Completed

T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

Non-small Cell Lung Cancer Stage III | Non-Small-Cell Lung Cancer Metastatic

China
First People's Hospital of Hangzhou

Completed

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Non-small Cell Lung Cancer Stage III | Non-Small-Cell Lung Cancer Metastatic

China
Gradalis, Inc.

Withdrawn

Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer

Lung Neoplasms | Advanced Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

Small Cell Lung Cancer | Solid Tumor | Non-small Cell Lung Cancer
BIND Therapeutics

Completed

A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer

Squamous Cell Non-small Cell Lung Cancer | KRAS Positive Patients With Non-small Cell Lung Cancer

United States, Russian Federation
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057)

Non-Squamous Cell Non-small Cell Lung Cancer

United States, Germany, Hong Kong, Spain, Australia, Mexico, Austria, France, Singapore, Switzerland, Canada, Poland, Argentina, Brazil, Chile, Czechia, Hungary, Italy, Norway, Peru, Romania, Russian Federation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer

Advanced Non-squamous Cell Non-small Cell Lung Cancer

China
Calithera Biosciences, Inc

Terminated

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

Non-Small Cell Lung Cancer | Non-squamous Non-small-cell Lung Cancer | Non-Squamous Non-Small Cell Neoplasm of Lung | KEAP1 Gene Mutation | NFE2L2 Gene Mutation | NRF2 Mutation

United States
Chugai Pharmaceutical
Japan Lung Cancer Society

Completed

Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)

Non-small Cell Lung Cancer | Extensive Disease Small Cell Lung Cancer

Japan
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Large Cell Lung Cancer | Adenosquamous Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung...

United States
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Active, not recruiting

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Canada, Ireland, Peru, South Africa
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Nonsmall Cell Lung Cancer | Carcinoma，Non-Small-Cell Lung | Non-small-cell Lung Carcinoma | Lung Carcinomas, Non-Small-Cell

Spain, Australia, Belarus, Brazil, Bulgaria, Chile, China, Colombia, Czechia, Georgia, Greece, Hungary, Jordan, Lebanon, Malaysia, Mexico, Philippines, Poland, Romania, Russian Federation, Taiwan, Thailand, Turkey, Ukraine
Chugai Pharmaceutical
Japan Lung Cancer Society

Completed

The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)

Non-small Cell Lung Cancer | Extensive Disease Small Cell Lung Cancer

Japan
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom
Danish Lung Cancer Group
Odense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Herlev Hospital and other collaborators

Recruiting

Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC

Radiotherapy Side Effect | Stage IV Non-small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer

Denmark
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer

Recurrent Lung Non-Small Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States, Canada
Mirati Therapeutics Inc.

Active, not recruiting

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

Advanced Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Italy, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom, China, Romania, Netherlands, Hong Kong, Austria, Belgium, Czechia, Hungary, Portugal, Greece, Germany, Ireland, Switze... and more
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
AstraZeneca

Completed

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

France, Korea, Republic of, United Kingdom, Spain
Intergroupe Francophone de Cancerologie Thoracique

Completed

Her2-positive Lung Cancer Treated With Dedicated Drug (R2D2)

Non Small Cell Lung Cancer Metastatic | HER2 Gene Mutation | Non Small Cell Lung Cancer Stage III

France
National Cancer Institute, Naples

Active, not recruiting

MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer (MILES-4)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB

Italy
Megan Daly, MD
National Cancer Institute (NCI); Genentech, Inc.

Terminated

MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Shandong Boan Biotechnology Co., Ltd

Completed

Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects

Metastatic Colorectal Cancer | Non Small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer Recurrent

China

Clinical Trials on Non Small Cell Lung

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Oman

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations